Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
This Medical News article discusses the safety and effectiveness of lecanemab and donanemab in treating mild cognitive impairment and early Alzheimer disease outside clinical trials.
Why it matters
This news article discusses the safety and effectiveness of lecanemab and donanemab for mild cognitive impairment and early Alzheimer disease outside clinical trials. It reports on the growing real-world experience rather than presenting new trial data.
-
41/100
BackgroundThere are limited studies quantifying the extent to which neighborhood deprivation affects mortality in individuals living with Alzheimer's disease (AD) and AD-related dementias (AD/ADRD).ObjectiveTo quantify to what extent neighborhood deprivation affects adverse outcomes in individuals living with AD/ADRD.MethodsWe identified individuals with AD/ADRD using a 15% random sample of national Medicare fee-for-service beneficiaries.
Why it matters
Among Medicare beneficiaries with AD/ADRD, higher area deprivation index quartiles were associated with higher odds of all-cause mortality compared to the lowest quartile. The study identifies neighborhood deprivation as an independent risk factor for mortality, but does not test any treatment, cure, or prevention.
-
MAP-RTAP (AUC = 0.78) and pTau/Aβ42 (AUC = 0.76) were the best performing individual biomarkers.
Why it matters
Advanced diffusion MRI biomarkers performed comparably to CSF biomarkers for classifying mild cognitive impairment, and combining C-NDI with Aβ42/Aβ40 achieved the highest performance with an AUC of 0.84. This is about enhancing early detection, not treating, curing or preventing Alzheimer's disease.
-
There are increasing calls for sharing individual biomarker results with participants in dementia research.
Why it matters
This perspective argues that Alzheimer's disease biomarker results are valid, interpretable, and actionable in people with dementia with Lewy bodies, and that there is an ethical imperative to study sharing these results with them. It is about disclosure practices and research ethics, not about treating or curing disease.
-
Accurate identification of neurodegenerative disorders, including Alzheimer’s Disease (AD) and Frontotemporal Dementia (FTD), is crucial for prompt medical intervention.
Why it matters
An EEG-based ensemble classification framework achieved high accuracy in differentiating Alzheimer's disease, frontotemporal dementia, and cognitively normal individuals. Results suggest combining EEG signal analysis with ensemble learning techniques could enhance clinical decision making for early identification of dementia-related disorders.
-
The model achieves accuracy rates of 94% on the brain tumor dataset, 81% on the augmented Alzheimer dataset, and 93% on the third dataset, underscoring its capability to differentiate various neurological conditions.
Why it matters
A deep learning model classified brain tumor and Alzheimer's MRI scans with reported accuracy of 94%, 81%, and 93% across datasets, and used SHAP to show which scan regions drove its decisions. It is a diagnostic tool study, not a treatment or cure, and the design is not stated.
-
Neurofilament light chain (NfL) conventionally reflects disability worsening in multiple sclerosis (MS), but does not necessarily imply MS-specific mechanisms and could be affected by biological or pathological aging, including Alzheimer disease (AD) pathology.
Why it matters
This study looked at a blood marker of nerve damage and Alzheimer's blood biomarkers in people over 65 who have multiple sclerosis. It is about measuring biomarkers in this group, not about treating, curing or preventing Alzheimer's disease.
-
In the base-case analysis from the healthcare perspective, SoC was more clinically effective than BSC with a cost per QALY of $5211.
Why it matters
In this cost-effectiveness analysis for Brazil, standard of care was the most cost-effective option, while lecanemab versus standard of care cost $2,098,225 per quality-adjusted life year gained and donanemab versus lecanemab cost $1,460,400. These figures concern cost and value, not whether the drugs cure or prevent Alzheimer disease.
-
The study highlights the potential of integrating 18 F-FDG-PET with CSF biomarkers to improve the diagnosis, prognosis, and monitoring of AD, emphasizing the complexity and regional specificity of biomarker interactions in neurodegeneration.
Why it matters
Brain glucose uptake on FDG-PET was related to several fluid and imaging Alzheimer's biomarkers and to cognitive scores in patients with memory problems. This helps clarify how these biomarkers relate to each other, but it does not test any treatment or prevention.
-
The association of Swiss Memory Clinics (SMC) provides intersocietal recommendations for the use of anti-amyloid monoclonal antibodies (mAbs) in Switzerland.
Why it matters
Swiss dementia experts produced shared recommendations for how anti-amyloid monoclonal antibodies should be used in Switzerland, including standards for clinics that give them. These are expert consensus recommendations, not new trial results on whether the drugs work.
-
Our results emphasize the role of fluid biomarkers in diagnosing dementia in low‐resource settings in South Asians.
Why it matters
In a clinic-based cohort in India, serum GFAP and NfL levels were higher in people with dementia than controls and showed high diagnostic accuracy. These biomarkers may aid diagnosis in low-resource settings, but the study does not test any treatment or prevention.
-
Addressing disparities related to Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD) is a priority for policymakers, practitioners, and researchers.
Why it matters
This perspective paper describes gaps in data, health information technology, and insurance models that affect disparities in Alzheimer's and related dementias care. It offers recommendations for future research and policy rather than testing any treatment, cure, or prevention.
-
41/100
CSF BD‐tau shows potential as a biomarker of treatment effect in AD but not bvFTD.
Why it matters
Cerebrospinal fluid brain-derived tau decreased after sodium selenate treatment in the Alzheimer's disease cohort but showed no change in behavioral variant frontotemporal dementia or in p-tau217 in either cohort. This suggests brain-derived tau may be a biomarker of treatment effect in Alzheimer's disease but not frontotemporal dementia, and further research is needed.
-
Alzheimer's disease (AD) is the most common neurodegenerative disorder that leads to progressive cognitive decline and imposes a significant socio-economic burden.
Why it matters
This review describes emerging non-traditional biomarkers, such as salivary, urinary, blood-based, microRNA, lipid and inflammatory markers, that may allow earlier and less invasive detection of Alzheimer's disease. It is about improving diagnosis and monitoring, not about curing or preventing the disease.
-
Alzheimer's disease (AD) is an age-associated neurodegenerative disorder with a complex etiology.
Why it matters
This review examines evidence that microglia take up, break down, and produce fructose and that this may be linked to metabolic changes in aging and Alzheimer's disease. It evaluates targeting fructose metabolism as a way to modulate microglial function but does not show a treatment.
-
A total of 156 patients were clinically diagnosed with dementia based on the 2011 NIA-AA criteria, regardless of specific disease etiology, and all exhibited significant brain atrophy on anatomical magnetic resonance imaging (MRI), indicating neuronal injury (N+).
Why it matters
In 156 patients already diagnosed with dementia, certain plasma markers (the Aβ42/40 ratio, pTau181 and GFAP) tracked with the presence of brain amyloid, while plasma NfL, Aβ42 and Aβ40 did not differ between groups. This is a diagnostic association study, not a treatment trial, so it does not show that measuring these blood markers changes or prevents disease.
-
Amyloidoses, which are characterized by abnormal accumulation of amyloid proteins leading to organ dysfunction, represent a major therapeutic challenge.
Why it matters
This review discusses proteolytic approaches—immunotherapy, PROTAC and photo-oxygenation—for removing amyloid proteins in amyloidoses including Alzheimer's disease. It reports promising in vitro and in vivo results for inhibiting amyloid aggregation and enhancing clearance, but these are not established treatments.
-
FTD patients performed significantly worse than HCs in most of the subtests of the basic emotion recognition batteries, where, instead, AD patients were significantly impaired only when required to match emotional facial expression in different individuals (subtask of the FERB).
Why it matters
This study found that frontotemporal dementia patients showed deficits in emotion recognition affecting both basic and social emotions, while Alzheimer's disease patients had fewer and specific deficits. It does not test any treatment, so it does not show a cure or prevention.
-
Neural autoantibodies are being increasingly detected in conjunction with neurodegenerative dementias such as Alzheimer's disease dementia (AD), yet their significance is not well clarified.
Why it matters
This single case report describes long-lasting KCNA2 antibodies in one 77-year-old man with biomarker-supported Alzheimer's disease. As one case report, it cannot show that these antibodies cause, treat, cure or prevent the disease.
-
Metabolomics provide a promising tool for understanding dementia pathogenesis and identifying novel biomarkers.
Why it matters
This study found differences in amino acid levels in the blood of people with Alzheimer's disease compared to healthy controls and those with vascular dementia, but no significant difference between healthy controls and vascular dementia patients. Certain amino acids showed promise as potential markers, but more research is needed before they could be used clinically.
-
86.8% of patients in this cohort presented more than one pathology.
Why it matters
Most people in this dementia cohort had more than one brain pathology, and hippocampal grey matter shrinkage was mainly linked to hippocampal sclerosis and Alzheimer's pathology, while white matter hyperintensities were most strongly linked to vascular and tau pathology. The authors say these mixed findings highlight the need for thorough pathology evaluation when studying dementia, which could help refine diagnostic protocols.
-
Vascular burden influences NfL levels, particularly in A- individuals at a symptomatic stage.
Why it matters
In 1221 memory clinic participants, plasma neurofilament light rose stepwise with combined amyloid and vascular pathology, and both amyloid and small vessel disease score were independently linked to higher levels. The authors note the effect of small vessel disease on neurofilament light was stronger in people without amyloid pathology.
-
We observed differential cellular effects on β-amyloid, pTau217 and cognitive measures.
Why it matters
This study found that polygenic risk scores weighted toward different cell types had different effects on β-amyloid and tau biomarkers, with microglial scores showing stronger effects on tau. It suggests that future research should address specific cell types for different aspects of Alzheimer disease, but no treatment is tested.
-
• EEG microstate analyses were performed in a cohort of autosomal dominant AD. • Coverage of class C decreased in symptomatic mutation carriers • Coverage of class D decreased in presymptomatic and symptomatic mutation carriers. • Coverage of class E increased in presymptomatic and symptomatic mutation carriers. • The findings may support presymptomatic changes in resting-state neuronal networks.
Why it matters
In families with autosomal dominant Alzheimer's disease, EEG microstate coverage differed in presymptomatic and symptomatic mutation carriers compared with non-carriers, which may reflect early changes in resting-state neuronal networks. This is a small EEG study and does not test any treatment, cure or prevention.
-
APOE ε4 is associated with accelerated progression of AD pathology.
Why it matters
In 575 Alzheimer's patients, carriers of the APOE ε4 gene variant had higher spinal fluid t-tau and p-tau 181 and higher blood LDL cholesterol than non-carriers. Some links between blood fats or antibodies and spinal fluid markers appeared only in carriers, and the authors note these blood molecules relate to inflammation and fat metabolism. They suggest this may shed light on APOE ε4's role in Alzheimer's and help diagnosis and treatment, though this is a single snapshot in time.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Considering sex and gender in Alzheimer disease and other dementias
- The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals
- The contribution of neuroinflammation to amyloid toxicity in Alzheimer's disease
- The global research of magnetic resonance imaging in Alzheimer’s disease: a bibliometric analysis from 2004 to 2023
- NPTX2 and cognitive dysfunction in Alzheimer's Disease
- Circulating Vitamin D Levels and Alzheimer's Disease: A Mendelian Randomization Study in the IGAP and UK Biobank
- Cerebral Microhemorrhage at MRI in Mild Cognitive Impairment and Early Alzheimer Disease: Association with Tau and Amyloid β at PET Imaging
- Brain tau PET-based identification and characterization of subpopulations in patients with Alzheimer’s disease using deep learning-derived saliency maps
- The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review
- A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment